BNP PARIBAS ASSET MANAGEMENT Holding S.A. Boosts Stock Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 31.9% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 454,538 shares of the biopharmaceutical company's stock after purchasing an additional 109,892 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. owned approximately 0.43% of Intra-Cellular Therapies worth $33,258,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Perceptive Advisors LLC raised its stake in shares of Intra-Cellular Therapies by 62.6% in the 2nd quarter. Perceptive Advisors LLC now owns 1,716,407 shares of the biopharmaceutical company's stock valued at $117,557,000 after acquiring an additional 661,052 shares during the period. Millennium Management LLC boosted its position in shares of Intra-Cellular Therapies by 214.5% during the second quarter. Millennium Management LLC now owns 889,102 shares of the biopharmaceutical company's stock worth $60,895,000 after buying an additional 606,358 shares during the period. Avoro Capital Advisors LLC raised its holdings in shares of Intra-Cellular Therapies by 21.2% in the 2nd quarter. Avoro Capital Advisors LLC now owns 3,000,000 shares of the biopharmaceutical company's stock valued at $205,470,000 after buying an additional 525,000 shares during the period. Marshall Wace LLP acquired a new position in Intra-Cellular Therapies during the 2nd quarter worth about $34,178,000. Finally, Hood River Capital Management LLC acquired a new position in Intra-Cellular Therapies in the 2nd quarter valued at about $33,390,000. Institutional investors and hedge funds own 92.33% of the company's stock.

Insider Activity

In other news, CEO Sharon Mates sold 40,513 shares of the company's stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $73.58, for a total value of $2,980,946.54. Following the completion of the sale, the chief executive officer now directly owns 1,070,329 shares of the company's stock, valued at approximately $78,754,807.82. This represents a 3.65 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, President Michael Halstead sold 22,869 shares of the firm's stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $89.12, for a total value of $2,038,085.28. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 97,778 shares of company stock valued at $7,524,436. 2.60% of the stock is currently owned by company insiders.

Intra-Cellular Therapies Stock Performance

NASDAQ ITCI opened at $85.69 on Friday. The company has a fifty day moving average of $79.05 and a two-hundred day moving average of $74.66. Intra-Cellular Therapies, Inc. has a 1 year low of $58.14 and a 1 year high of $93.45.

Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last posted its earnings results on Wednesday, October 30th. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.07). The firm had revenue of $175.40 million during the quarter, compared to analysts' expectations of $172.30 million. Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. The firm's revenue for the quarter was up 39.0% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.25) earnings per share. As a group, analysts predict that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on ITCI shares. Cantor Fitzgerald reissued an "overweight" rating and issued a $130.00 price objective on shares of Intra-Cellular Therapies in a research note on Monday, September 16th. JPMorgan Chase & Co. raised their price target on shares of Intra-Cellular Therapies from $81.00 to $89.00 and gave the company an "overweight" rating in a research report on Monday, November 4th. Royal Bank of Canada upped their price objective on Intra-Cellular Therapies from $106.00 to $108.00 and gave the stock an "outperform" rating in a research report on Friday, October 4th. Needham & Company LLC reiterated a "buy" rating and issued a $100.00 target price on shares of Intra-Cellular Therapies in a report on Wednesday, October 30th. Finally, UBS Group cut their price target on Intra-Cellular Therapies from $83.00 to $79.00 and set a "neutral" rating on the stock in a report on Thursday, August 8th. Two analysts have rated the stock with a hold rating and eleven have given a buy rating to the company's stock. Based on data from MarketBeat, Intra-Cellular Therapies presently has a consensus rating of "Moderate Buy" and an average target price of $97.23.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.